South & Central America Long-Term Injectable Drug Delivery Market Size and Forecast (2021

Description

List of Tables

The South and Central America Long-Term Injectable Drug Delivery Market is projected to reach US$ 499.0 Million by 2034, increasing from US$ 256.3 Million in 2025. The market is expected to register a CAGR of 7.7% during the forecast period from 2026 to 2034.

Executive Summary and South and Central America Long-Term Injectable Drug Delivery Market Analysis:

The South and Central America Long-Term Injectable Drug Delivery Market, segmented into Brazil, Argentina, and the Rest of South & Central America, is witnessing consistent growth as healthcare systems increasingly adopt treatment solutions designed for prolonged drug release. The growing incidence of chronic conditions, including diabetes, cardiovascular diseases, cancer, and other long-term disorders, is creating greater demand for injectable therapies that can maintain therapeutic drug levels while reducing the frequency of administration.

Improving healthcare awareness and the modernization of medical infrastructure are supporting access to advanced drug delivery technologies, particularly in major markets such as Brazil and Mexico. Long-acting injectable formulations are gaining attention because they can simplify treatment schedules and potentially improve adherence among patients requiring prolonged therapy.

The expanding use of biologic medicines and biosimilars is another factor contributing to market development. Many of these therapies require specialized injectable delivery systems capable of maintaining product stability and providing controlled administration. Advances in formulation technologies, including polymer-based systems, microspheres, depot formulations, and sustained-release mechanisms, are improving the performance and convenience of long-term injectable products.

Government programs focused on chronic disease management, healthcare accessibility, and treatment outcomes are also helping create favorable conditions for market expansion. In addition, pharmaceutical companies are increasing research and development activities to address unmet therapeutic needs and introduce more patient-friendly delivery solutions.

As healthcare providers increasingly emphasize adherence, convenience, and cost-effective long-term disease management, the adoption of long-acting injectable therapies is expected to expand across South and Central America. Continued investment in healthcare infrastructure, pharmaceutical innovation, and advanced delivery devices should further strengthen the regional market over the coming years.

Strategic Insights

South and Central America Long-Term Injectable Drug Delivery Market Segmentation Analysis:

By Formulation Packaging (Ready-to-Use), the South and Central America Long-Term Injectable Drug Delivery Market is segmented into Ampoules, Vials, Cartridges, and Bottles. The Vials segment dominated the market in 2025.

By Therapeutic Application, the market is categorized into Diabetes, Oncology, Auto-Immune Disorders, Cardiovascular Diseases, Infectious Diseases, Pain Management, and Others. The Diabetes segment held the largest share in 2025.

By Route of Administration, the market is divided into Subcutaneous, Intramuscular, Intravenous, and Others. The Subcutaneous segment represented the leading category in 2025.

By Usability, the market comprises Disposable Injectors and Re-usable Injectors. Disposable Injectors accounted for the dominant share in 2025.

By End User, the market is segmented into Pharmaceutical and Biopharma Companies and CMOs and CDMOs. Pharmaceutical and Biopharma Companies held the leading position in 2025.

Market Report Scope

South and Central America Long-Term Injectable Drug Delivery Market Outlook

The increasing adoption of long-acting biologics and biosimilars in oncology and autoimmune disease treatment is creating significant opportunities for long-term injectable drug delivery technologies. Patients managing chronic and debilitating illnesses frequently require extended treatment, making simplified dosing schedules an important consideration for adherence and quality of life. Long-acting formulations can provide therapeutic exposure for longer periods while reducing the number of injections required.

Ustekinumab is an example of a long-acting biologic used for moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Following initial loading doses, it can be administered subcutaneously at extended intervals. In oncology supportive care, pegfilgrastim is a long-acting granulocyte colony-stimulating factor that can be administered through a single subcutaneous injection during each chemotherapy cycle to help reduce the risk of febrile neutropenia in eligible patients.

The growing availability of biosimilars is further contributing to treatment accessibility. Regulatory authorities have approved biosimilar versions of products such as pegfilgrastim and ustekinumab after evaluations of their analytical characteristics, clinical performance, safety, and immunogenicity. These products provide healthcare systems with additional treatment alternatives and may improve affordability while maintaining established therapeutic standards.

The rising burden of chronic diseases throughout South and Central America is reinforcing the need for therapies that can support long-term disease management. As healthcare systems place greater emphasis on patient-centered care, reducing treatment complexity and improving medication adherence is becoming increasingly important.

Long-term injectable technologies can address these requirements by extending dosing intervals, reducing injection frequency, and minimizing the burden associated with repeated administration. Continued development of biologics, biosimilars, and sustained-release formulations is therefore expected to support further innovation and adoption in oncology and autoimmune disease care.

South and Central America Long-Term Injectable Drug Delivery Market Country Insights

By country, the South and Central America Long-Term Injectable Drug Delivery Market is segmented into Brazil, Argentina, and the Rest of South and Central America. Brazil held the largest market share in 2025.

Brazil represents the region's largest market for long-term injectable drug delivery, supported by its substantial population, developing healthcare infrastructure, and significant burden of chronic diseases. Diabetes, HIV, and cancer are among the conditions creating demand for treatment approaches that can provide sustained drug exposure and simplify long-term medication schedules.

According to the International Diabetes Federation (IDF) Diabetes Atlas 2024, approximately 16.6 million adults aged 20-79 years in Brazil were living with diabetes, with an age-standardized prevalence of approximately 10.6%. The substantial diabetic population creates opportunities for long-acting insulin and other injectable therapies designed to support consistent disease management.

HIV also remains an important healthcare concern. Brazil's Ministry of Health has reported more than 1.16 million cumulative AIDS cases since 1980, while annual HIV infections have remained significant in recent years. Cancer contributes further to the country's healthcare burden, with the National Cancer Institute (INCA) projecting approximately 704,000 new cancer cases during the 2023-2025 period.

These conditions often require prolonged treatment, making extended-release formulations and convenient injectable devices increasingly relevant. Reduced administration frequency can help address treatment fatigue while supporting adherence and continuity of care.

Brazil is also progressing in the adoption of innovative long-acting HIV prevention technologies. ANVISA has received a priority review submission for lenacapavir, a twice-yearly subcutaneous HIV prevention therapy, while the country has incorporated cabotegravir as a long-acting pre-exposure prophylaxis option. Regulatory changes allowing more efficient joint ethical and regulatory assessments of clinical research are also expected to accelerate development and access to advanced therapies.

Together, these initiatives demonstrate Brazil's growing focus on innovative drug delivery and patient-centered treatment. Continued investment through the public healthcare system, pharmaceutical sector, and regulatory infrastructure is expected to support long-term injectable drug delivery adoption across the country.

South and Central America Long-Term Injectable Drug Delivery Market Company Profiles

Key companies operating in the South and Central America Long-Term Injectable Drug Delivery Market include Terumo Corp, Phillips-Medisize, Gerresheimer AG, West Pharmaceutical Services Inc, Ypsomed Holding AG, Schott AG, AptarGroup Inc, Becton Dickinson and Co, Owen Mumford Ltd, and SHL Medical.

These companies are pursuing strategies including geographic expansion, product innovation, strategic partnerships, manufacturing investments, and mergers and acquisitions. Such initiatives are intended to strengthen injectable delivery portfolios, improve device convenience and functionality, expand production capabilities, and capture emerging opportunities across the regional long-term drug delivery market.

Product Code: TIPRE00044024

1. Executive Summary

1.1 Analyst Market Outlook

2. Global Long-Term Injectable Drug Delivery Market Landscape

2.1 Overview
2.2 Value Chain Analysis
2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
2.4 Porter's Five Forces Analysis
2.5 PEST Analysis

3. Competitive Landscape

3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2025 - By Key Players
3.3 Market Concentration

4. South and Central America Long-Term Injectable Drug Delivery Market - Key Industry Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints:

5. Long-Term Injectable Drug Delivery Market - South and Central America Analysis

5.1 South and Central America Long-Term Injectable Drug Delivery Market Revenue (US$ Million), 2021 - 2034
5.2 South and Central America Long-Term Injectable Drug Delivery Market Revenue Forecast and Analysis

6. South and Central America Long-Term Injectable Drug Delivery Market Revenue Analysis - by Formulation Packaging (ready-to-use)

6.1 South and Central America Long-Term Injectable Drug Delivery Market Forecast and Analysis by Formulation Packaging (ready-to-use)
- 6.1.1 Ampoules
  - 6.1.1.1 Overview
  - 6.1.1.2 Ampoules: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.2 Vials
  - 6.1.2.1 Overview
  - 6.1.2.2 Vials: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.3 Cartridges
  - 6.1.3.1 Overview
  - 6.1.3.2 Cartridges: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.4 Bottles
  - 6.1.4.1 Overview
  - 6.1.4.2 Bottles: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

7. South and Central America Long-Term Injectable Drug Delivery Market Revenue Analysis - by Therapeutic Application

7.1 South and Central America Long-Term Injectable Drug Delivery Market Forecast and Analysis by Therapeutic Application
- 7.1.1 Diabetes
  - 7.1.1.1 Overview
  - 7.1.1.2 Diabetes: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.2 Oncology
  - 7.1.2.1 Overview
  - 7.1.2.2 Oncology: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.3 Auto-Immune Disorders
  - 7.1.3.1 Overview
  - 7.1.3.2 Auto-Immune Disorders: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.4 Cardiovascular Diseases
  - 7.1.4.1 Overview
  - 7.1.4.2 Cardiovascular Diseases: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.5 Infectious Diseases
  - 7.1.5.1 Overview
  - 7.1.5.2 Infectious Diseases: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.6 Pain Management
  - 7.1.6.1 Overview
  - 7.1.6.2 Pain Management: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.7 Others
  - 7.1.7.1 Overview
  - 7.1.7.2 Others: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

8. South and Central America Long-Term Injectable Drug Delivery Market Revenue Analysis - by Route Of Administration

8.1 South and Central America Long-Term Injectable Drug Delivery Market Forecast and Analysis by Route Of Administration
- 8.1.1 Subcutaneous
  - 8.1.1.1 Overview
  - 8.1.1.2 Subcutaneous: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.2 Intramuscular
  - 8.1.2.1 Overview
  - 8.1.2.2 Intramuscular: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.3 Intravenous
  - 8.1.3.1 Overview
  - 8.1.3.2 Intravenous: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.4 Others
  - 8.1.4.1 Overview
  - 8.1.4.2 Others: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

9. South and Central America Long-Term Injectable Drug Delivery Market Revenue Analysis - by Usability

9.1 South and Central America Long-Term Injectable Drug Delivery Market Forecast and Analysis by Usability
- 9.1.1 Disposable Injectors
  - 9.1.1.1 Overview
  - 9.1.1.2 Disposable Injectors: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 9.1.2 Re-usable Injectors
  - 9.1.2.1 Overview
  - 9.1.2.2 Re-usable Injectors: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

10. South and Central America Long-Term Injectable Drug Delivery Market Revenue Analysis - by End User

10.1 South and Central America Long-Term Injectable Drug Delivery Market Forecast and Analysis by End User
- 10.1.1 Pharmaceutical and Biopharma Companies
  - 10.1.1.1 Overview
  - 10.1.1.2 Pharmaceutical and Biopharma Companies: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 10.1.2 CMOs and CDMOs
  - 10.1.2.1 Overview
  - 10.1.2.2 CMOs and CDMOs: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

11. South and Central America Long-Term Injectable Drug Delivery Market - Country Analysis

11.1 South and Central America
- 11.1.1 South and Central America Long-Term Injectable Drug Delivery Market Forecast and Analysis - by Country
  - 11.1.1.1 Brazil Market
    - 11.1.1.1.1 Brazil: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.1.2 Brazil: South and Central America Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.1.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.1.2.2 Therapeutic Application
      - 11.1.1.1.2.3 Route Of Administration
      - 11.1.1.1.2.4 Usability
      - 11.1.1.1.2.5 End User
  - 11.1.1.2 Argentina Market
    - 11.1.1.2.1 Argentina: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.2.2 Argentina: South and Central America Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.2.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.2.2.2 Therapeutic Application
      - 11.1.1.2.2.3 Route Of Administration
      - 11.1.1.2.2.4 Usability
      - 11.1.1.2.2.5 End User
  - 11.1.1.3 Rest of South and Central America Market
    - 11.1.1.3.1 Rest of South and Central America: South and Central America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.3.2 Rest of South and Central America: South and Central America Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.3.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.3.2.2 Therapeutic Application
      - 11.1.1.3.2.3 Route Of Administration
      - 11.1.1.3.2.4 Usability
      - 11.1.1.3.2.5 End User

12 Long-Term Injectable Drug Delivery Market Industry Landscape

13 - Key Company Profiles

13.1 Terumo Corp
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Phillips-Medisize
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Gerresheimer AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 West Pharmaceutical Services Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Ypsomed Holding AG
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Schott AG
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 AptarGroup Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Becton Dickinson and Co
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Owen Mumford Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 SHL Medical
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 Glossary
14.2 Research Methodology and Approach
- 14.2.1 Secondary Research
- 14.2.2 Primary Research
- 14.2.3 Market Estimation Approach
  - 14.2.3.1 Supply Side Analysis
  - 14.2.3.2 Demand Side Analysis
- 14.2.4 Research Assumptions and Limitations
- 14.2.5 Currency Conversion
14.3 About The Insight Partners
14.4 Market Intelligence Cloud